FMP

FMP

Enter

AIM ImmunoTech Inc. (AMEX:AIM) Insider Purchase and Financial Challenges

- (Last modified: Nov 21, 2024 9:02 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Equels Thomas K, CEO of AIM ImmunoTech Inc. (AMEX:AIM), purchased 60,110 shares, indicating confidence in the company's future.
  • AIM announced promising results from a Phase 1 study on Ampligen® for TNBC but highlighted the need for larger studies.
  • The company is facing financial difficulties with a negative P/E ratio, high price-to-sales ratio, and potential liquidity issues.

AIM ImmunoTech Inc. (AMEX:AIM) is a biotechnology company focused on developing therapies for immune system disorders and cancer. The company is known for its drug Ampligen®, which is being studied for various medical applications. AIM operates in a competitive biotech industry, where it faces challenges from other companies developing similar treatments.

On November 20, 2024, Equels Thomas K, AIM's director, CEO, and President, purchased 60,110 shares of the company's Common Stock at $0.183 each. This transaction increased his total ownership to 1,552,968 shares. This move might reflect his confidence in AIM's future prospects, despite the company's current financial challenges.

AIM recently announced the publication of data from a Phase 1 study conducted by Roswell Park Comprehensive Cancer Center. The study evaluated Ampligen® for early-stage triple-negative breast cancer (TNBC). The results, published in The Journal for ImmunoTherapy of Cancer, showed promise, but Dr. Shipra Gandhi emphasized the need for larger studies to validate these findings.

Financially, AIM is facing difficulties. It has a negative price-to-earnings (P/E) ratio of -0.47, indicating ongoing losses. The price-to-sales ratio is high at 65.15, meaning investors pay $65.15 for every dollar of sales. The enterprise value to sales ratio is even higher at 78.23, reflecting a high valuation relative to sales.

AIM's balance sheet shows a debt-to-equity ratio of 0.13, indicating low debt levels. However, the current ratio is 0.75, suggesting potential liquidity issues. The negative enterprise value to operating cash flow ratio of -0.72 and earnings yield of -2.14% highlight challenges in generating positive cash flow and earnings.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep